Literature DB >> 7589507

GCAP-II: isolation and characterization of the circulating form of human uroguanylin.

R Hess1, M Kuhn, P Schulz-Knappe, M Raida, M Fuchs, J Klodt, K Adermann, V Kaever, Y Cetin, W G Forssmann.   

Abstract

The systematic isolation of circulating regulatory peptides which generate cGMP as second messenger resulted in the identification of a novel member of the guanylin family. In the present study we describe the purification and amino acid sequence of a new guanylate cyclase C activating peptide (GCAP-II). GCAP-II contains 24 amino acids in the following sequence: FKTLRTIANDDCELCVNVACTGCL. Its molecular mass is 2597.7 Da. The 16 C-terminal amino acids are identical to uroguanylin from human urine. native and synthetic GCAP-II activate GC-C, the specific guanylate cyclase receptor, of cultured human colon carcinoma (T84) cells. GCAP-II stimulates chloride secretion in isolated human intestinal mucosa mediated by intracellular cGMP increase. GCAP-II specific antibodies were used to localize the peptide by immunohistochemistry in entero-endocrine cells of the colonic mucosa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589507     DOI: 10.1016/0014-5793(95)01075-p

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Expression of type II cGMP-dependent protein kinase in rat kidney is regulated by dehydration and correlated with renin gene expression.

Authors:  S Gambaryan; C Häusler; T Markert; D Pöhler; T Jarchau; U Walter; W Haase; A Kurtz; S M Lohmann
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Structural and phylogenetic characterization of human SLURP-1, the first secreted mammalian member of the Ly-6/uPAR protein superfamily.

Authors:  K Adermann; F Wattler; S Wattler; G Heine; M Meyer; W G Forssmann; M Nehls
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

3.  Natriuretic and antikaliuretic effects of uroguanylin and prouroguanylin in the rat.

Authors:  Nicholas G Moss; Dorothy A Riguera; Robert C Fellner; Christopher Cazzolla; Michael F Goy
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-22

4.  Lack of guanylate cyclase C results in increased mortality in mice following liver injury.

Authors:  Elizabeth A Mann; Kumar Shanmukhappa; Mitchell B Cohen
Journal:  BMC Gastroenterol       Date:  2010-08-02       Impact factor: 3.067

5.  The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomers.

Authors:  Nicholas G Moss; Dorothy A Riguera; Robert M Solinga; Marco M Kessler; Daniel P Zimmer; William J Arendshorst; Mark G Currie; Michael F Goy
Journal:  Hypertension       Date:  2009-03-16       Impact factor: 10.190

6.  Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enteral NaCl load.

Authors:  John N Lorenz; Michelle Nieman; Jenine Sabo; L Philip Sanford; Jennifer A Hawkins; Noeet Elitsur; Lara R Gawenis; Lane L Clarke; Mitchell B Cohen
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

7.  Liquid chromatography and electrospray mass spectrometric mapping of peptides from human plasma filtrate.

Authors:  M Raida; P Schulz-Knappe; G Heine; W G Forssmann
Journal:  J Am Soc Mass Spectrom       Date:  1999-01       Impact factor: 3.109

8.  Occurrence and localization of uroguanylin in the aging human prostate.

Authors:  Caroline Maake; Franziska Auf der Maur; Katarina Jovanovic; Manfred Reinecke; Dieter Hauri; Hubert John
Journal:  Histochem Cell Biol       Date:  2002-12-21       Impact factor: 4.304

9.  Circulating prouroguanylin is processed to its active natriuretic form exclusively within the renal tubules.

Authors:  Xun Qian; Nicholas G Moss; Robert C Fellner; Michael F Goy
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

10.  Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide.

Authors:  Nicholas G Moss; Robert C Fellner; Xun Qian; Sharon J Yu; Zhiping Li; Masamitsu Nakazato; Michael F Goy
Journal:  Endocrinology       Date:  2008-05-22       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.